A recent study provides Class I evidence that the self-generation behavioral intervention (self-GEN) improves memory, self-regulation, functional status, affective symptomatology, and quality of life (QoL) in patients with multiple sclerosis (MS). Researchers conducted a double-blind, placebo-controlled, randomized clinical trial that included 35 participants with clinically definite MS, 19 in the treatment group, and 16 in the placebo control group. Participants completed a baseline neuropsychological assessment, including questionnaires assessing everyday memory and a repeat assessment immediately post-treatment. They found:

• The treatment group showed significantly improved learning and memory, self-regulation, and metacognition relative to the placebo post-treatment.
• Similar results were noted on measures of depression, functional status, and QoL.